Advances in purification of SARS-CoV-2 spike ectodomain protein using high-throughput screening and non-affinity methods.

ABSTRACT: The spike (S) glycoprotein of the pandemic virus, SARS-CoV-2, is a critically important target of vaccine design and therapeutic development. A high-yield, scalable, cGMP-compliant downstream process for the stabilized, soluble, native-like S protein ectodomain is necessary to meet the extensive material requirements for ongoing research and development. As of June 2021, S proteins have exclusively been purified using difficult-to-scale, low-yield methodologies such as affinity and size-exclusion chromatography. Herein we present the first known non-affinity purification method for two S constructs, S_dF_2P and HexaPro, expressed in the mammalian cell line, CHO-DG44. A high-throughput resin screen on the Tecan Freedom EVO200 automated bioprocess workstation led to identification of ion exc

SUBMITTER: Cibelli N 

PROVIDER: S-EPMC8923338 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature